Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACH-0137171 in Chronic Hepatitis C
NCT00401947Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ACH-0137171 in hepatitis C (HCV) (4 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Safety and Tolerability, Pharmacokinetics and 2 more. Started Nov 2006; status: terminated.
02
Drugs
ACH-0137171
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00401947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00401947.